<!DOCTYPE html SYSTEM "about:legacy-compat">
<html class="no-js">
  <head>
    <meta charset="utf-8"/>
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
    <title>DC Code - § 48–902.08. Schedule III enumerated.</title>
    <meta property="st:title" content="§ 48–902.08. Schedule III enumerated."/>
    <meta name="description" content="A simple, free browser for the Washington, DC Code"/>
    <meta name="viewport" content="width=device-width"/>
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,400,700" rel="stylesheet" type="text/css"/>
    <link rel="stylesheet" type="text/css" href="/css/reset.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/site.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/body.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/print.css" media="print"/>
    <link rel="stylesheet" type="text/css" href="/css/icons/style.css" media="screen"/>
    <script type="text/javascript">
            var _paq = _paq || [];
            _paq.push(['trackPageView']);
            _paq.push(['enableLinkTracking']);
            (function() {
              var u="//analytics.code.dccouncil.us/";
              _paq.push(['setTrackerUrl', u+'piwik.php']);
              _paq.push(['setSiteId', 1]);
              var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];
              g.type='text/javascript'; g.async=true; g.defer=true; g.src=u+'piwik.js'; s.parentNode.insertBefore(g,s);
            })();

          window.searchHost = 'https://search.code.dccouncil.us';
          window.queryUrl = '/v1/search';
          </script>
    <noscript>
      <p>
        <img src="//analytics.code.dccouncil.us/piwik.php?idsite=1" style="border:0;" alt=""/>
      </p>
    </noscript>
  </head>
  <body>
    <header>
      <section class="container">
        <div class="right no-print search" id="search"> </div>
        <h1 id="sitename">
          <a href="/dc/council/code/">Code of the District of Columbia</a>
        </h1>
      </section>
    </header>
    <main class="main container">
      <div class="clearfix" style="width: 100%;">
        <aside id="sidebar" class="col4 quiet">
          <h2>You Are Here</h2>
          <ul class="ancestors">
            <li>↪ <a href="/">D.C. Law Library</a></li>
            <li>↪ <a href="/dc/council/code/">Code of the District of Columbia</a></li>
            <li>↪ <a href="/dc/council/code/titles/48/">Title 48. Foods and Drugs.</a></li>
            <li>↪ <a href="/dc/council/code/titles/48/chapters/9/">Chapter 9. Controlled Substances Act.</a></li>
            <li>↪ <a href="/dc/council/code/titles/48/chapters/9/subchapters/II/">Subchapter II. Standards and Schedules.</a></li>
            <li>↪ § 48–902.08. Schedule III enumerated.</li>
          </ul>
          <h2>Previous</h2>
          <p>
            <a href="/dc/council/code/sections/48-902.07.html">§ 48–902.07. Schedule III tests.</a>
          </p>
          <h2>Next</h2>
          <p>
            <a href="/dc/council/code/sections/48-902.09.html">§ 48–902.09. Schedule IV tests.</a>
          </p>
          <h2>Publication Information</h2>
          <h3>Current through November 26, 2016</h3>
          <dl id="recency">
            <dt>Last codified D.C. Law:</dt>
            <dd>
          Law 21-167 effective November 26, 2016</dd>
            <dt>Last codified Emergency Law:</dt>
            <dd>
          Act 21-354 effective March 23, 2016</dd>
            <dt>Last codified Federal Law:</dt>
            <dd>
          Public Law 114-118 approved January 28, 2016</dd>
          </dl>
          <section class="cta">
            <p>
              <a href="mailto:code@dccouncil.us?subject=[ERROR]+/dc/council/code/sections/48-902.08.html">Report Error</a>
            </p>
            <p>
              <a href="mailto:code@dccouncil.us?subject=[FEEDBACK]+/dc/council/code/sections/48-902.08.html">Website Feedback</a>
            </p>
            <p>We cannot respond to questions regarding the law.</p>
          </section>
        </aside>
        <section class="col8 body"><h1>§ 48–902.08. Schedule III enumerated.</h1> <section class="content"><section><section class="line-group primary-content"><p class="text-indent-1"><span class="level-num">(a)</span> The controlled substances listed in this section are included in Schedule III, unless and until removed therefrom pursuant to § <a class="internal-link" href="/dc/council/code/sections/48-902.01.html">48-902.01</a>:</p><p class="text-indent-2"><span class="level-num">(1)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p><p class="text-indent-3"><span class="level-num">(A)</span> Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;</p><p class="text-indent-3"><span class="level-num">(B)</span> Benzphetamine;</p><p class="text-indent-3"><span class="level-num">(C)</span> Chlorphentermine;</p><p class="text-indent-3"><span class="level-num">(D)</span> Chlortermine;</p><p class="text-indent-3"><span class="level-num">(E)</span> Mazindol; and</p><p class="text-indent-3"><span class="level-num">(F)</span> Phendimetrazine;</p><p class="text-indent-2"><span class="level-num">(2)</span> Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:</p><p class="text-indent-3"><span class="level-num">(A)</span> Any compound, mixture, or preparation containing:</p><p class="text-indent-4"><span class="level-num">(i)</span> Amobarbital;</p><p class="text-indent-4"><span class="level-num">(ii)</span> Secobarbital; or</p><p class="text-indent-4"><span class="level-num">(iii)</span> Pentobarbital; or any salt thereof and 1 or more other active medicinal ingredients which are not listed in any schedule;</p><p class="text-indent-3"><span class="level-num">(B)</span> Any suppository dosage form containing:</p><p class="text-indent-4"><span class="level-num">(i)</span> Amobarbital;</p><p class="text-indent-4"><span class="level-num">(ii)</span> Secobarbital;</p><p class="text-indent-4"><span class="level-num">(iii)</span> Pentobarbital; or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;</p><p class="text-indent-3"><span class="level-num">(C)</span> Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid:</p><p class="text-indent-4"><span class="level-num">(i)</span> Chlorhexadol;</p><p class="text-indent-4"><span class="level-num">(ii)</span> Rescheduled to Schedule II;</p><p class="text-indent-4"><span class="level-num">(iii)</span> Lysergic acid;</p><p class="text-indent-4"><span class="level-num">(iv)</span> Lysergic acid amide;</p><p class="text-indent-4"><span class="level-num">(v)</span> Methyprylon;</p><p class="text-indent-4"><span class="level-num">(vi)</span> Sulfondiethylmethane;</p><p class="text-indent-4"><span class="level-num">(vii)</span> Sulfonethylmethane;</p><p class="text-indent-4"><span class="level-num">(viii)</span> Sulfonmethane;</p><p class="text-indent-4"><span class="level-num">(ix)</span> Tiletamine &amp; Zolazepam Combination Product; and</p><p class="text-indent-4"><span class="level-num">(x)</span> Vinbarbital;</p><p class="text-indent-2"><span class="level-num">(3)</span> Nalorphine;</p><p class="text-indent-2"><span class="level-num">(4)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:</p><p class="text-indent-3"><span class="level-num">(A)</span> Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;</p><p class="text-indent-3"><span class="level-num">(B)</span> Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p class="text-indent-3"><span class="level-num">(C)</span> Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a 4-fold or greater quantity of an isoquinoline alkaloid of opium;</p><p class="text-indent-3"><span class="level-num">(D)</span> Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p class="text-indent-3"><span class="level-num">(E)</span> Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p class="text-indent-3"><span class="level-num">(F)</span> Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more ingredients in recognized therapeutic amounts;</p><p class="text-indent-3"><span class="level-num">(G)</span> Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts; and</p><p class="text-indent-3"><span class="level-num">(H)</span> Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p class="text-indent-2"><span class="level-num">(5)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, drug, or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progesterons, and corticorsteroids) that promotes muscle growth and includes:</p><p class="text-indent-3"><span class="level-num">(A)</span> Boldenone;</p><p class="text-indent-3"><span class="level-num">(B)</span> Chlortestosterone (4-chlortestosterone);</p><p class="text-indent-3"><span class="level-num">(C)</span> Clostebol;</p><p class="text-indent-3"><span class="level-num">(D)</span> Dehydrochlormethyltestosterone;</p><p class="text-indent-3"><span class="level-num">(E)</span> Dihydrotestosterone (4-dihydrotestosterone);</p><p class="text-indent-3"><span class="level-num">(F)</span> Drostanolone;</p><p class="text-indent-3"><span class="level-num">(G)</span> Ethylestrenol;</p><p class="text-indent-3"><span class="level-num">(H)</span> Fluoxymestorone;</p><p class="text-indent-3"><span class="level-num">(I)</span> Formebulone (formebolone);</p><p class="text-indent-3"><span class="level-num">(J)</span> Mesterolone;</p><p class="text-indent-3"><span class="level-num">(K)</span> Methandienone;</p><p class="text-indent-3"><span class="level-num">(L)</span> Methandranone;</p><p class="text-indent-3"><span class="level-num">(M)</span> Methandriol;</p><p class="text-indent-3"><span class="level-num">(N)</span> Methandrostenolone;</p><p class="text-indent-3"><span class="level-num">(O)</span> Methenolone;</p><p class="text-indent-3"><span class="level-num">(P)</span> Methyltestosterone;</p><p class="text-indent-3"><span class="level-num">(Q)</span> Mibolerone;</p><p class="text-indent-3"><span class="level-num">(R)</span> Nandrolone;</p><p class="text-indent-3"><span class="level-num">(S)</span> Norethandrolone;</p><p class="text-indent-3"><span class="level-num">(T)</span> Oxandrolone;</p><p class="text-indent-3"><span class="level-num">(U)</span> Oxymesterone;</p><p class="text-indent-3"><span class="level-num">(V)</span> Oxymetholone;</p><p class="text-indent-3"><span class="level-num">(W)</span> Stanolone;</p><p class="text-indent-3"><span class="level-num">(X)</span> Stanozolol;</p><p class="text-indent-3"><span class="level-num">(Y)</span> Testolactone;</p><p class="text-indent-3"><span class="level-num">(Z)</span> Testosterone;</p><p class="text-indent-3"><span class="level-num">(AA)</span> Trenbolone; and</p><p class="text-indent-3"><span class="level-num">(BB)</span> Any salt, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by Secretary of Health and Human Services for such administration. If any person prescribes, dispenses or distributes such steroid for human use such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph;</p><p class="text-indent-2"><span class="level-num">(6)</span> Cannabis; and</p><p class="text-indent-2"><span class="level-num">(7)</span><span class="level-num">(A)</span> Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</p><p class="text-indent-3"><span class="level-num">(B)</span><span class="level-num">(i)</span> For the purposes of this paragraph, the term “cannabimimetic agents” means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:</p><p class="text-indent-5"><span class="level-num">(I)</span> 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.</p><p class="text-indent-5"><span class="level-num">(II)</span> 3-(1-naphthoyl)indole or 3-(1- naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.</p><p class="text-indent-5"><span class="level-num">(III)</span> 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.</p><p class="text-indent-5"><span class="level-num">(IV)</span> 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.</p><p class="text-indent-5"><span class="level-num">(V)</span> 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.</p><p class="text-indent-4"><span class="level-num">(ii)</span> The term “cannabimimetic agents” includes:</p><p class="text-indent-5"><span class="level-num">(I)</span> (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c] chromen-1-ol)(HU-210);</p><p class="text-indent-5"><span class="level-num">(II)</span> 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (CP 47,497);</p><p class="text-indent-5"><span class="level-num">(III)</span> 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog);</p><p class="text-indent-5"><span class="level-num">(IV)</span> 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);</p><p class="text-indent-5"><span class="level-num">(V)</span> 1-butyl-3-(1-naphthoyl)indole (JWH-073);</p><p class="text-indent-5"><span class="level-num">(VI)</span> 1-hexyl-3-(1-naphthoyl)indole (JWH- 019);</p><p class="text-indent-5"><span class="level-num">(VII)</span> 1-[2-(4-morpholinyl)ethyl]-3-(1- naphthoyl)indole (JWH-200);</p><p class="text-indent-5"><span class="level-num">(VIII)</span> 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);</p><p class="text-indent-5"><span class="level-num">(IX)</span> 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);</p><p class="text-indent-5"><span class="level-num">(X)</span> 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH- 122);</p><p class="text-indent-5"><span class="level-num">(XI)</span> 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH- 398);</p><p class="text-indent-5"><span class="level-num">(XII)</span> 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);</p><p class="text-indent-5"><span class="level-num">(XIII)</span> 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);</p><p class="text-indent-5"><span class="level-num">(XIV)</span> 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR- 19 and RCS-4);</p><p class="text-indent-5"><span class="level-num">(XV)</span> 1-cyclohexylethyl-3-(2- methoxyphenylacetyl)indole (SR-18 and RCS-8); and</p><p class="text-indent-5"><span class="level-num">(XVI)</span> 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).</p><p class="text-indent-1"><span class="level-num">(b)</span> The Mayor may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains 1 or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.</p></section><br/><section class="line-group annotations"><p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§208">Aug. 5, 1981, D.C. Law 4-29, § 208, 28 DCR 3081</a>; amended by rule, 39 DCR 1882; amended by rule Dec. 7, 1994, 41 DCR 7967; <a class="internal-link" href="/dc/council/laws/13-300.html">June 8, 2001, D.C. Law 13-300, § 2(a), 47 DCR 7037</a>; <a class="internal-link" href="/dc/council/laws/19-320.html">June 19, 2013, D.C. Law 19-320, § 301(d), 60 DCR 3390</a>.)
    </p><h4>Prior Codifications</h4><p>1981 Ed., § 33-518.</p><h4>Section References</h4><p>This section is referenced in § <a class="internal-link" href="/dc/council/code/sections/7-3002.html">7-3002</a>, § <a class="internal-link" href="/dc/council/code/sections/44-1201.html">44-1201</a>, § <a class="internal-link" href="/dc/council/code/sections/48-853.01.html">48-853.01</a>, § <a class="internal-link" href="/dc/council/code/sections/48-902.01.html">48-902.01</a>, § <a class="internal-link" href="/dc/council/code/sections/48-902.02.html">48-902.02</a>, and § <a class="internal-link" href="/dc/council/code/sections/48-1004.html">48-1004</a>.</p><h4>Effect of Amendments</h4><p><a class="internal-link" href="/dc/council/laws/13-300.html">D.C. Law 13-300</a>, in subsec. (a), deleted “and” at the end of par. (4)(H), substituted “; and” for the period at the end of par. (5)(BB), and added par. (6).</p><p>The 2013 amendment by <a class="internal-link" href="/dc/council/laws/19-320.html">D.C. Law 19-320</a> added (a)(7); and made related changes.</p><h4>Emergency Legislation</h4><p>For temporary amendment of (a), see § 301(d) of the Omnibus Criminal Code Amendments Emergency Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013,  60 DCR 1017).</p><p>For temporary (90 days) amendment of this section, see § 301(d) of the Omnibus Criminal Code Amendment Congressional Review Emergency Act of 2013 (D.C. Act 20-44, April 1, 2013,  60 DCR 5381, 20 DCSTAT 1281).</p><h4>Temporary Legislation</h4><p>For temporary (225 days) amendment of this section, see § 2(c) of Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2016 (D.C. Law 21-131, July 1, 2016, 63 DCR 7110).</p></section></section></section></section>
      </div>
    </main>
    <footer>
      <section class="container center">
        <p>The codes and laws on this website are in the public domain.</p>
        <p>
              Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/dc-law-html">HTML</a> or <a href="https://github.com/dccouncil/dc-law-xml">XML</a>.
            </p>
      </section>
    </footer>
    <script type="text/javascript" src="/js/search.js"> </script>
  </body>
</html>
